Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Takeda’s Pevonedistat Gets 1st Sakigake Tag under PMD Law
August 26, 2021
- COVID-19 Antibody Cocktail to Be Made Available for Outpatients Too: Minister
August 25, 2021
- Orphan Status Granted to Fenfluramine, Asciminib, Vosoritide
August 25, 2021
- Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
- PAFSC to Review Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug and More
August 24, 2021
- Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
- MHLW to Seek Budget to Boost GMP Inspections to Secure Trust in Generics: FY2022 Request
August 23, 2021
- New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
August 23, 2021
- Sharp Drop in Suspected Violations Seen in FY2020 Drug Promotion, but Comparison Difficult due to COVID-19: MHLW
August 23, 2021
- MHLW’s FY2022 Budget Request to Focus on COVID-19 R&D, Quality Generic System
August 20, 2021
- Japan Panel OKs COVID-19 Vaccine Health Damage Claims for First Time
August 20, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
- Public-Private Dialogue for New Pharma Vision Set for Aug. 24
August 18, 2021
- Otsuka’s Eczema Med, Alexion’s Blood Thinner Antidote Up for PAFSC Review on Aug. 30
August 17, 2021
- 14 Firms Flock to Get Approval for E Keppra Generics towards December Listing
August 17, 2021
- MHLW OKs Ronapreve Use in Short-Term Hospitalization and at Accommodation Facilities
August 17, 2021
- Kono Says Vaccine Rollout Sped Up as Japan Hits 100 Million Dose Mark
August 11, 2021
- Japan to Run Follow-Up Survey for AstraZeneca Vaccine at 6 Hospitals
August 11, 2021
- Prefectural Governors Urge Booster Shot with AstraZeneca Jabs
August 11, 2021
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…